Alnylam: Amvuttra's Launch And Ongoing Clinical Progress Are Positives (NASDAQ:ALNY)

Alnylam stands out in biotech with strong revenue growth, a robust pipeline, and proven commercial success. Read why ALNY stock is a Buy.